Trimedyne, Inc. reported financial results for the second quarter and six months ended March 31, 2018. For the quarter ended March 31, 2018, the company reported revenues of $1,352,000, an increase of 21% from revenues of $1,119,000 for the prior year quarter. The company had a net income for the current quarter of $24,000 or $0.20 per share, as compared to a net loss of $31,000 or $0.25 per share for the prior year quarter. The net income during the current quarter as compared to a net loss during the prior year quarter is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of the cost controls. For the six-month period ended March 31, 2018, the company reported revenues of $2,886,000, an increase of 30% from revenues of $2,213,000 for the prior year six-month period. The company had net income for the current six-month period of $110,000 or $0.90 per share, as compared to a net loss of $256,000 or $2.09 per share for the prior year six-month period. The net income during the current six-month period as compared to a net loss during the prior year six-month period is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of the cost controls.